Diaxxo

What Diaxxo does

Diaxxo AG is a Swiss medical device company founded in 2020 as a spin-off of ETH Zürich's Functional Materials Laboratory, headquartered in Zürich with regional sales offices in Germany, Turkey, and Singapore. The company develops compact, point-of-care RT-qPCR (reverse transcription quantitative polymerase chain reaction) systems for rapid molecular diagnostics, comprising instrument platforms (the diaxxoPCR amplification device, the diaxxoExtractor sample-preparation unit, and the integrated diaxxoCare all-in-one platform) paired with proprietary single-use diaxxoPod cartridges pre-loaded with dry reagents targeting SARS-CoV-2, variants of concern, Malaria, STIs, Dengue, Monkeypox, Borreliosis, Schistosomiasis, Helminths, E. Coli, and Avian Influenza. Its core technical differentiator is a low-thermal-mass aluminum cartridge and high-power LED/CCD optical architecture enabling extreme thermocycling rates and complete sample-to-result workflows in under 45 minutes.

The business operates a razor-and-blade commercial model: instruments are sold through a direct website-based inquiry system with regional sales contacts covering Europe, the Middle East, and Asia-Pacific, while diaxxoPod and extraction cartridges generate recurring consumable revenue. Pricing is quote-based and not publicly disclosed, though the company positions its cost-per-test at under 10 EUR versus more than 100 EUR for outsourced PCR services. Customers span small-to-medium point-of-care clinical laboratories, veterinary diagnostic operations, environmental/water testing programs, and government or NGO-led global-health deployments, including Schistosomiasis screening in Zanzibar and African-European SARS-CoV-2 partnership projects. The company also offers field-deployed accessories (electricity-free diaxxoSwab and instrument-free diaxxoRod for vector-sample extraction) and field-grade consumables stable at room temperature, eliminating cold-chain requirements. As of available data, Diaxxo has approximately 13 team members, is privately held, has not disclosed any venture equity funding, and has been funded primarily through the ETH Pioneer Fellowship and a Swiss National Science Foundation grant alongside operating revenues.

Name

Diaxxo

Legal name

diaxxo AG

Website

https://diaxxo.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Diaxxo AG is a Zürich-based medtech company that develops compact RT-qPCR diagnostic platforms (diaxxoPCR, diaxxoExtractor, diaxxoCare) and proprietary diaxxoPod cartridges, enabling rapid, low-cost molecular testing at the point of care for human, veterinary, and environmental applications worldwide.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Equipment

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

akta.pro secondary industries

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Infectious Disease POCT (Respiratory, STI, HIV, Sepsis) (HLAHAOAA), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

Keywords

• Molecular diagnostics
• RT-PCR testing equipment
• Point-of-care diagnostics
• PCR test cartridges
• Nucleic acid extraction

Headquarters

HQ city

Zurich

HQ country

Switzerland

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. RT-qPCR Hardware Platforms: Sale of diagnostic instruments including diaxxoPCR (RT-qPCR amplification device), diaxxoExtractor (sample extraction device), and diaxxoCare (All-in-One platform). These are one-time hardware purchases.
2. PCR Consumables (diaxxoPod Cartridges): Recurring sale of proprietary test cartridges pre-loaded with reagents for specific disease detection (Covid-19, variants, Malaria, STIs, Dengue, Monkeypox, Borreliosis, Schistosomiasis, Helminths, E. Coli, Avian Influenza). Sold in sets of 12 cartridges (96 tests). Ongoing consumable revenue as tests are performed.
3. Extraction Consumables: DNA/RNA extraction cartridges for use with diaxxoExtractor. Contain magnetic beads and chemicals for processing 1-16 samples in parallel. Stable at room temperature.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Diaxxo develops and sells compact RT-qPCR (real-time polymerase chain reaction) diagnostic instruments and proprietary pre-loaded test cartridges that enable rapid, affordable molecular DNA/RNA testing at the point of care. Its product line spans standalone amplification devices (diaxxoPCR), sample extraction devices (diaxxoExtractor), an all-in-one integrated platform (diaxxoCare), and dry-reagent diaxxoPod cartridges for detecting pathogens such as SARS-CoV-2, Malaria, STIs, Dengue, Monkeypox, Schistosomiasis, Avian Influenza, and Borreliosis.

Product overview

Diaxxo offers a modular PCR testing platform consisting of three instrument tiers (diaxxoPCR for amplification only, diaxxoExtractor for sample preparation only, and diaxxoCare as the All-in-One integrated solution), paired with two consumable cartridge types (diaxxoPod for PCR amplification and the Extraction Cartridge for DNA/RNA purification). The platform is complemented by two standalone extraction accessories (diaxxoSwab and diaxxoRod) designed for field use without electricity. The diaxxoPod cartridges support multiple disease targets including SARS-CoV-2, variants of concern, Monkeypox, Dengue, Malaria, Schistosomiasis, Borreliosis, Helminths, E. Coli, Avian Influenza, and STIs. All consumables feature room-temperature stability and pre-loaded reagents to minimize hands-on time and eliminate cold chain requirements.

Differentiator

Problem solved

Functional benefit

Products and services

• diaxxoPCR Compact RT-qPCR amplification device (25x25 cm footprint, 5 kg) with CCD optical sensor, high-power LED excitation and fixed optical path. Performs real-time quantitative PCR for DNA/RNA amplification and detection, delivering results in under 30 minutes. Targeted at small and medium laboratories and point-of-care facilities.
• diaxxoExtractor Desktop DNA/RNA extraction device using magnetic beads extraction methods. Processes 8 samples per run with short processing time and minimal hands-on time, preparing samples for downstream PCR amplification. Used by laboratories and clinics requiring efficient sample preparation.
• diaxxoCare Integrated All-in-One device (50x50 cm, 10 kg) that combines sample extraction and real-time qPCR amplification in a single benchtop unit. Delivers complete RT-qPCR testing including extraction in under 45 minutes and handles 200 µL sample volumes, eliminating the need for separate instruments.
• diaxxoPod Proprietary in-vitro diagnostic test cartridge with all reagents (MasterMix, additives, primers, controls) pre-loaded in dry form. Sold in sets of 12 cartridges (96 tests) for disease targets including SARS-CoV-2, Covid-19 variants of concern, Malaria, STIs, Dengue, Monkeypox, Borreliosis, Schistosomiasis, Helminths, E. Coli and Avian Influenza. Stable at room temperature, eliminating cold chain requirements.
• Extraction Cartridge DNA/RNA extraction cartridge containing all necessary chemicals for magnetic beads extraction of 1–16 samples in parallel. Storable at room temperature with extraction time under 15 minutes. Used in conjunction with the diaxxoExtractor or diaxxoCare devices.
• diaxxoSwab Stand-alone, electricity-free sample extraction platform that brings nucleic acid purification to remote testing facilities and field laboratories. Performs 8 extractions per kit, delivering sample-to-extracted nucleic acids in 3 minutes without external equipment.
• diaxxoRod

Quantifiable outcome

• RT-PCR results in <45 minutes vs 5 days for outsourced testing
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cepheid (Danaher): Cepheid's GeneXpert system is the benchmark cartridge-based real-time PCR platform for point-of-care molecular diagnostics, covering infectious diseases including SARS-CoV-2, TB, STIs, and tropical diseases. Directly comparable technology category and cartridge architecture to Diaxxo's diaxxoPCR/diaxxoPod platform.
• bioMérieux (BioFire): BioFire FilmArray is a leading closed-cartridge multiplex PCR system used in clinical and field settings for syndromic infectious disease panels. Directly competes in the rapid molecular POCT space with similar workflow and consumable model.
• Qiagen: Qiagen's QIAstat-Dx is a cartridge-based multiplex real-time PCR system designed for point-of-care syndromic testing. Comparable cartridge architecture, workflow simplicity, and disease panel approach to Diaxxo's diaxxoCare and diaxxoPod.
• Molbio Diagnostics: Molbio's Truenat is a chip-based real-time PCR platform widely deployed across LMICs for diseases including TB, HIV, HPV, and tropical pathogens. Closest comparable peer to Diaxxo's positioning in cost-sensitive and resource-limited settings.
• Bosch Healthcare Solutions: Bosch's Vivalytic is a cartridge-based PCR platform for rapid molecular testing at point-of-care. Comparable miniaturized form factor, cartridge architecture, and target use cases (infectious disease testing in clinical and field settings).

Broad incumbents

• Roche Diagnostics: Roche's cobas Liat system is a compact, rapid PCR platform targeting point-of-care and urgent care settings. As a broad incumbent with global distribution, Roche is the most directly comparable large-scale competitor; Diaxxo's strategic advisor is a former Roche executive.
• Abbott: Abbott offers the ID NOW rapid molecular platform for point-of-care testing alongside the m2000 high-throughput system. Comparable in molecular diagnostics product range and target customer base, though broader portfolio across diagnostics.
• QuidelOrtho: QuidelOrtho offers Sofia and Triage rapid diagnostic platforms spanning immunoassays and molecular testing. Broader incumbent in rapid diagnostics with overlapping presence in point-of-care testing channels.
• Hologic: Hologic's Panther system is a high-throughput molecular diagnostics platform widely used for infectious disease testing. Comparable molecular diagnostics technology category though focused on centralized labs rather than POCT.

Emerging players

• Bioneer: Bioneer offers ExiStation and AccuPower molecular diagnostic systems with pre-loaded dry reagent PCR kits targeting infectious disease testing. Comparable emerging player with similar dry-reagent cartridge approach and focus on decentralized PCR.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/diaxxo-ag/?originalSubdomain=ch

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diaxxo